EYEN - Eyenovia's Stock Is Soaring Today - Here's Why | Benzinga
William Blair initiated coverage on Eyenovia Inc (NASDAQ: EYEN), a biopharma company focused on developing therapies based on its Optejet device, which leverages a microdose array print (MAP) technology that allows consistent, reproducible dosing of ophthalmic drugs.
Analysts Tim Lugo, Lachlan Hanbury-Brown, and John Boyle have initiated an Outperform rating, with an estimated fair value for shares of $3.
The fair value is based on a risk-adjusted net present value (NPV) for MydCombi, APP13007, and the company's clinical-stage pipeline of two additional assets using the Optejet technology as well as royalties and milestones from U.S. and ex-U.S. partnerships.
The company recently received approval for MydCombi, which will be marketed to the eye care ...